NCT04115566

Brief Summary

Hidradenitis suppurativa (HS) is a common and debilitating skin disease that is poorly understood and understudied. As a result, little is known about disease prognosis and few effective treatments exist for this condition. This prospective observational cohort study aims to comprehensively characterize the clinical and biological features of HS. The results of this research will provide a basis for the development of an HS clinical classification system and identification of potential treatments for HS.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3,000

participants targeted

Target at P75+ for all trials

Timeline
109mo left

Started Aug 2020

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress39%
Aug 2020May 2035

First Submitted

Initial submission to the registry

September 18, 2019

Completed
16 days until next milestone

First Posted

Study publicly available on registry

October 4, 2019

Completed
10 months until next milestone

Study Start

First participant enrolled

August 1, 2020

Completed
14.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2035

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2035

Last Updated

April 29, 2026

Status Verified

April 1, 2026

Enrollment Period

14.8 years

First QC Date

September 18, 2019

Last Update Submit

April 28, 2026

Conditions

Hidradenitis Suppurativa

Outcome Measures

Primary Outcomes (1)

  • Primary Objective

    The primary aim of this study is to identify clinical and biologic characteristics of hidradenitis suppurativa.

    2019-2035

Secondary Outcomes (1)

  • Secondary Objective

    2019-2035

Eligibility Criteria

Age10 Years+
Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

HS Patients

You may qualify if:

  • Male or female ≥ 10 years of age
  • Diagnosis of HS by a dermatologist or practitioner experienced in making a diagnosis of HS
  • Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.

You may not qualify if:

  • \. Inability to give informed consent or unavailability of a parent/guardian who is able and willing to give informed consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of California San Francisco

San Francisco, California, 94115, United States

RECRUITING

MeSH Terms

Conditions

Hidradenitis Suppurativa

Condition Hierarchy (Ancestors)

Skin Diseases, BacterialBacterial InfectionsBacterial Infections and MycosesInfectionsSkin Diseases, InfectiousSuppurationSkin DiseasesSkin and Connective Tissue DiseasesHidradenitisSweat Gland Diseases

Study Officials

  • Haley B Naik, MD, MHSc, FAAD

    University of California, San Francisco

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Kaelin Chatterley

CONTACT

415-961-3786hsprogress@ucsf.edu

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
10 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 18, 2019

First Posted

October 4, 2019

Study Start

August 1, 2020

Primary Completion (Estimated)

May 1, 2035

Study Completion (Estimated)

May 1, 2035

Last Updated

April 29, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations

US(1)